Too Much or Too Little? Individualizing GFR Assessments and Multidisciplinary Dose Adjustment of Anticancer Therapies in Patients with CKD and ESKD
Back to course
Video Transcription
Video Summary
Asset Caption
Paul Hanna, MD, MSc, FASN; Thomas D. Nolin, PharmD, PhD, FASN
Meta Tag
Speaker Paul Hanna
Speaker Thomas D. Nolin
Keywords
kidney function
anticancer drug dosing
creatinine-based eGFR
cystatin C
measured GFR
chemotherapy dosing
carboplatin